Results 21 to 30 of about 20,950 (257)

Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? [PDF]

, 2017
No abstract ...
McInnes, Iain B., Porter, Duncan, Siebert, Stefan   +2 more
core   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs

Mediators of Inflammation, 2020
Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the
Yu Zhou, Jinhui Ma, Juncheng Ge, Bailiang Wang, Debo Yue, Weiguo Wang   +5 more
doaj   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]

, 2018
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M, Liao, Wilson, Yang, Eric J   +2 more
core   +1 more source

Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis [PDF]

, 2016
In this phase III, double-blind, placebo-controlled study, 606 patients with psoriatic arthritis were randomised to intravenous (IV) secukinumab 10 mg/kg (weeks 0, 2, 4) followed by subcutaneous secukinumab 150 mg (IV→150 mg) or 75 mg (IV→75 mg), or ...
Aletaha, Day, Gladman, Gottlieb, Goulabchand, Heijde, Heijde, Heijde, Kavanaugh, Kavanaugh, McInnes, Mease, Mease, Mease, Mease, Menon, Ogdie, Rosen, Smolen   +18 more
core   +6 more sources

Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease

Vaccines, 2022
Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis.
Paolo Gisondi, Davide Geat, Martina Maurelli, Luca Degli Esposti, Francesco Bellinato, Giampiero Girolomoni   +5 more
doaj   +1 more source

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study [PDF]

, 2017
Objectives. To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. Methods. Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2,
Delicha, Eumorphia-Maria, Gottlieb, Alice B., Kajekar, Radhika, Kirkham, Bruce, McInnes, Iain B., Mease, Philip J., Mpofu, Shephard, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T.   +9 more
core   +2 more sources

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

RMD Open, 2018
Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436).Methods Following the 2-year core trial, eligible patients ...
Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop   +10 more
doaj   +1 more source

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis : Fundamentals Of Care for UveitiS (FOCUS) Initiative [PDF]

, 2018
Supplemental material available at www.aaojournal.org. Supported by AbbVie, Inc., and the Fundamentals of Care for Uveitis Initiative National Faculty.
Accorinti, Massimo, Acharya, Nisha, Adan, Alfredo, Agrawal, Rupesh, Akkoc, Nurullah, Al Ghamdi, Saed, Al Ghamdi, Turki, Al Saati, Anood, Al-Dhibi, Hassan A., Al-Shamarani, Mohamed, Alsabaani, Nasser, Bachta, Artur, Barisani-Asenbauer, Talin, Beare, Nicholas, Belfort, Rubens, Blanco, Ricardo, Brézin, Antoine P., Carreño, Ester, Chandran, Vinod, Chee, Soon Phaik, Chiquet, Christophe, Chng, Hiok Hee, Cimbalas, Andrius, Cimino, Luca, Cordero-Coma, Miguel, Cristobal, Couto, Cuevas, Miguel, Davis, Janet L., de Boer, Joke, de la Torre, Alejandra, De Schryver, Ilse, Derzko-Dzulynsky, Larissa, Diaz-Valle, David, Dick, Andrew D., Eurico da Fonseca, João, Facsko, Andrea, Figueira, Luis, Fundamentals of Care for Uveitis International Consensus Group, Kuffova, Lucia, Merino, Claudia Eugenia Duran, Murphy, Conor, Nascimento, Heloisa, Porto, Fernanda Belga Ottoni, Ramanan, Athimalaipet V., Rosenbaum, James T., Salah, Sawsen, Salek, Sherveen, Siak, Jay, Sonoda, Koh Hei, Steeples, Laura, Yee, Anita Chan Sook   +50 more
core   +4 more sources